Related Experiment Videos
[Esthesioneuroblastoma treatment].
E Gil-Carcedo1, L M Gil-Carcedo, L A Vallejo
1Cátedra de Otorrinolaringología, Departamento de Cirugía, Servicio de ORL y PCF, Hospital Universitario Rio Hortega, Universidad de Valladolid, SACYL. elisagilcarcedo@wanadoo.es
Acta Otorrinolaringologica Espanola
|December 16, 2005
Summary
Esthesioneuroblastoma treatment strategies are analyzed, revealing surgery combined with radiotherapy as common. This review of esthesioneuroblastoma (ENB) patients highlights survival rates and treatment patterns.
Area of Science:
- Oncology
- Otorhinolaryngology
Context:
- Esthesioneuroblastoma (ENB) is a rare cancer originating from the olfactory neuroepithelium.
- Optimal treatment and therapeutic strategies for ENB remain undefined.
Purpose:
- To analyze tumor behavior and identify ideal treatment, therapeutic strategies, and patterns of failure for esthesioneuroblastoma.
- To review published literature on ENB management between 1994 and 2004.
Summary:
- A review of 34 publications involving 583 patients found a 5-year survival rate of 51.2% for esthesioneuroblastoma.
- Surgery, alone or in combination, was the most frequent treatment (78%).
- Combined surgical and radiotherapy management was utilized in 47% of cases.
Impact:
- Provides insights into esthesioneuroblastoma treatment outcomes.
- Informs clinical decision-making for esthesioneuroblastoma management.
- Highlights the importance of multimodal treatment approaches in esthesioneuroblastoma.